Medicinova (MNOV) vs Nomad Power Solutions (NMAD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Medicinova (MNOV) has outperformed Nomad Power Solutions (NMAD) over the past year, gaining 26.2% versus a loss of 11.2%. Over five years, MNOV leads with a -59.7% price change compared with -77.2% for NMAD. Medicinova is the larger company by market cap ($74.8 million vs $72.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNOV | NMAD |
|---|---|---|
| Share price | $1.52 | $4.53 |
| Market cap | $74.82M | $72.94M |
| 1-day change | -1.30% | +6.09% |
| YTD return | +17.56% | +8.65% |
| 1-year return | +26.23% | -11.23% |
| 5-year return | -59.69% | -77.17% |
| EPS (TTM) | $-0.21 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.90 | $8.38 |
| 52-week low | $1.17 | $2.36 |
| Distance from 52-week high | -61.03% | -45.94% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +442.76% | — |
| Average volume | 322.57K | 273.42K |
| Shares outstanding | 49.22M | 16.10M |
| Employees | 6 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MNOV has outperformed NMAD by 37.5 percentage points over the past year.
About Medicinova
MNOV stock →MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees
About Nomad Power Solutions
NMAD stock →NOMAD Power Solutions, Inc. develops utility-scale mobile energy storage systems on providing transportable solutions.
Health Care · Biotechnology: Pharmaceutical Preparations
MNOV vs NMAD FAQ
Which is bigger, Medicinova or Nomad Power Solutions?
Medicinova (MNOV) is larger, with a market capitalization of $74.82M compared with $72.94M for Nomad Power Solutions (NMAD).
Which stock has performed better over the past year, MNOV or NMAD?
MNOV returned +26.23% over the past 12 months, compared with -11.23% for NMAD (price return, excluding dividends). Past performance does not predict future results.
Are Medicinova and Nomad Power Solutions in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.